Last reviewed · How we verify

NCT05306587

Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.

Completed Last updated 3 April 2024
What this trial tests

trial testing Darzalex in Multiple Myeloma in 40 participants. Completed in 1 January 2024.

Timeline
1 April 2022
Primary endpoint
15 December 2023
1 January 2024

Quick facts

Lead sponsorThomas Lund
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date1 April 2022
Primary completion15 December 2023
Estimated completion1 January 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Thomas Lund

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple myeloma (MM) is the second most common hematological disease in Denmark with an incidence of approximately 350 diagnosed cases per year. There is no curative treatment yet, but usually the disease is very sensitive to treatment, and patients have periods of varying length, where they do not require treatment. Thus the prognosis for MM has improved over recent years, and the rate of survival has been extended for both younger and elderly patients. With the increasing specialization and centralization that will occur in the coming years, some patients will have very long transport times to the hospital. When patients go to the hospital only to receive their anticancer therapy, their visits are relatively short and the amount of time spend on transportation might appear disproportionate. The frequent hospital appointments increase the patient's exposure for bacteria and viruses which should be calculated as a potential risk. Furthermore if the patient is an active part of the labor market, it can be challenging to request freedom to hospital visits. It is thus possible to provide the treatment at home, but it is unknown what significance it has for patients, relatives and health professionals as well as for the economy it is thus possible to provide the treatment at home, but it is unknown what significance it has for patients, relatives and health professionals as well as for the economy. The aim of this project is to investigate the home administration of Daratumumab SC reported by both patients and healthcare professionals compared to the hospital administration setting. Furthermore, this project investigates the hypothesis that the home administration of Daratumumab potentially can reduce the time associated with the administration, thereby, resulting in a socio-economic gain. The aim for this study: We want to examine patients 'and healthcare professionals' perspectives, the organizational and the socio economic aspects of administering subcutaneous Daratumumab in their own home to patients with multiple myeloma, and to illuminate the benefits and challenges of this.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Home-Based Daratumumab in Patients With Multiple Myeloma.
    Rosenberg T, Kirkegaard J, Gundesen MT, Rasmussen MK, et al · · 2025 · cited 2× · PMID 40165411 · DOI 10.1111/ejh.14409

Verify or expand the search:

Other trials of Darzalex

Trials testing the same drug.

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

Other Thomas Lund trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05306587.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing